| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
The Woodlands, Texas, November 5, 2026 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today reported financial results for the three months ended September 30, 2026, and provided an u... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
The Woodlands, Texas, August 6, 2026 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments. |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
The Woodlands, Texas, May 7, 2026 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments. |
| 06 May 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
The Woodlands, Texas, May 4, 2026 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC). that provides up to $100 million in borrowing capacity. A... |
| 30 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
LEXICON PHARMACEUTICALS, INC. 2026 EQUITY INCENTIVE PLAN This Plan was initially adopted by the Board and approved by the Company’s stockholders on September 13, 1995. The Plan was subsequently amended or amended and restated (each, an “... |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions |
| 02 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +3 more
Lexicon Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are ac... |
| 29 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
The Woodlands, Texas, January 29, 2026 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of ... |
| 10 Nov 2025 |
8-K: Other Events
On November 6, 2025, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with its previously announced Open Market Sale AgreementSM, dated December 29, 2023 (the “Agreement”), with Jefferies LLC, as sales... |
| 06 Nov 2025 |
8-K: Other Events
We have acted as counsel for Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), with respect to certain legal matters in connection with the proposed issuance and sale from time to time by the Company of common stock,... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND |
| 28 Jul 2025 |
8-K: Other Events
On July 23, 2025, we received a letter from the Listing Qualifications staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that we have regained compliance with Nasdaq's minimum $1 bid price requirement for our common stock and th... |
| 03 Jul 2025 |
8-K: Other Events
On July 3, 2025, we received a letter from the Listing Qualifications staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that we are eligible for an additional 180-calendar day period, or until December 30, 2025, in which to rega... |
| 03 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Submission of Matters to a Vote of Security Holders
Exhibit 10.1 LEXICON PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN This Plan initially was established as the Lexicon Genetics Incorporated 1995 Stock Option Plan (the “1995 Stock Option Plan”), which was adopted by the Board and appr... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain |
| 28 Mar 2025 |
8-K: Entry into a Material Definitive Agreement
Exhibit 10.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Seventh Ame... |
| 06 Mar 2025 |
8-K: Results of Operations and Financial Condition
Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development |
| 07 Jan 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On January 3, 2025, we received a letter (the “Notice”) from the Listing Qualifications staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the last 31 consecutive bus... |
| 02 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
I extend this offer for you to join us as Senior Vice President and Chief Financial Officer at Lexicon Pharmaceuticals, Inc. (the “Company”), reporting to the Chief Executive Officer. This position will be located in our Bridgewater, NJ ... |
Loading...